James B Sun

US Patent:

6611524, Aug 26, 2003

Filed:

Jun 30, 1999

Appl. No.:

09/340256

Inventors:

Harish Devanagondi - Fremont CA
James Sun - Mountain View CA

Assignee:

Cisco Technology, Inc. - San Jose CA

International Classification:

H04L 1256

US Classification:

3703955, 370474

Abstract:

A data packet parser, for determining packet format, is substantially software controlled, to readily accommodate new or different formats, without the need for using a microprocessor for parsing. Comparisons are performed under the control of data stored in a database. By storing new or different data in the database, new or different packet formats can accommodated without the need for making hardware changes. In one embodiment, comparisons performed on various fields of the data packet result in setting or clearing bits of a signature word which identifies the packet format. The signature word can be used directly or indirectly such as forming the input argument of a ternary CAM, to provide a pointer to microcode which appropriately handles the data packet in the identified format.

US Patent:

61699586, Jan 2, 2001

Filed:

Apr 9, 1999

Appl. No.:

9/289552

Inventors:

Vijay Nagasamy - Fremont CA
Mohammad Usman - Santa Clara CA
James Sun - Mountain View CA

Assignee:

VSIS, Inc. - Sunnyvale CA

International Classification:

G06F16500

US Classification:

701213

Abstract:

Systems and methods are disclosed for ionospheric correction in a system employing a single GPS frequency receiver for determining the geographic location of an object on the earth's surface. The receiver receives signals transmitted at the GPS L. sub. 1 frequency from at least first, second and third GPS satellites, the first, second and third satellites having respective orbital positions relative to the receiver such that the total electron count (TEC) contribution to ionoshperic interference to signals transmitted by the respective satellites and received by the receiver is approximately the same. Respective measured distances of the three satellites to the receiver are determined based on the actual signal transmission times. True distances of the respective satellites are then calculated based on the assumption that the TEC contribution to the interference from each satellite is approximately the same.

US Patent:

61632953, Dec 19, 2000

Filed:

Apr 9, 1999

Appl. No.:

9/289216

Inventors:

Vijay Nagasamy - Fremont CA
Mohammad Usman - Santa Clara CA
James Sun - Mountain View CA

Assignee:

VSIS, Inc. - Sunnyvale CA

International Classification:

H04B 7185

US Classification:

34235706

Abstract:

Systems and methods are disclosed for ionospheric correction in a system employing a single GPS frequency receiver for determining the geographic location of an object on the earth's surface. The receiver receives signals transmitted at the GPS L. sub. 1 frequency from at least first and second GPS satellites, the first and second satellites having respective orbital positions relative to the receiver such that the total electron count (TEC) contribution to ionoshperic interference to signals transmitted by the respective satellites and received by the receiver is approximately the same. Respective measured distances of the two satellites to the receiver are determined based on the actual signal transmission times. True distances of the respective satellites are then calculated based on the assumption that the TEC contribution to the interference from each satellite is approximately the same.

US Patent:

20220412981, Dec 29, 2022

Filed:

Mar 4, 2022

Appl. No.:

17/686565

Inventors:

- South San Francisco CA, US
- Cambridge MA, US
Priti HEGDE - South San Francisco CA, US
Marcin KOWANETZ - San Francisco CA, US
David SHAMES - South San Francisco CA, US
Philip J. STEPHENS - Cambridge MA, US
James Xin SUN - Cambridge MA, US
Roman YELENSKY - Newton MA, US
Wei ZOU - South San Francisco CA, US

International Classification:

G01N 33/574
C07K 16/28
C12Q 1/6886
A61P 35/04
A61P 35/00
A61K 38/17
A61K 39/395
A61K 45/06
C07K 14/705

Abstract:

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

US Patent:

20230020089, Jan 19, 2023

Filed:

May 4, 2022

Appl. No.:

17/736738

Inventors:

- Emeryville CA, US
Raphael Rousseau - Los Altos CA, US
Roman Yelensky - Newton MA, US
James Xin Sun - Newton MA, US
Matthew Joseph Davis - Scituate MA, US
Karin Jooss - Emeryville CA, US
Amy Rachel Rappaport - Daly City CA, US
Ciaran Daniel Scallan - San Francisco CA, US
Leonid Gitlin - Foster City CA, US
Christine Denise Palmer - Cambridge MA, US
Jennifer Busby - Burlington MA, US
Mojca Skoberne - Cambridge MA, US
Wade Blair - Gaithersburg MD, US

International Classification:

A61K 39/00
A61P 35/00
C12N 15/86
C12N 15/62

Abstract:

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime/boost vaccincation strategy.

US Patent:

20190219586, Jul 18, 2019

Filed:

Apr 1, 2019

Appl. No.:

16/371589

Inventors:

- South San Francisco CA, US
- Cambridge MA, US
Priti Hegde - South San Francisco CA, US
Marcin Kowanetz - South San Francisco CA, US
David Shames - South San Francisco CA, US
Philip J. Stephens - Cambridge MA, US
James Xin Sun - Cambridge MA, US
Roman Yelensky - Newton MA, US
Wei Zou - South San Francisco CA, US

International Classification:

G01N 33/574
A61P 35/00
C07K 16/28
C07K 14/705
A61K 45/06
C12Q 1/6886
A61K 39/395
A61K 38/17
A61P 35/04

Abstract:

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

US Patent:

20180371099, Dec 27, 2018

Filed:

Aug 28, 2018

Appl. No.:

16/115343

Inventors:

- South San Francisco CA, US
- Cambridge MA, US
Gregg FINE - South San Francisco CA, US
Garrett M. FRAMPTON - Cambridge MA, US
Priti HEGDE - South San Francisco CA, US
Sanjeev MARIATHASAN - South San Francisco CA, US
Philip J. STEPHENS - Cambridge MA, US
James Xin SUN - Cambridge MA, US
Roman YELENSKY - Newton MA, US

International Classification:

C07K 16/28
A61K 39/395
G16H 50/30
G16H 20/10

Abstract:

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).